X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SBT101 is the first clinical-stage adeno-associated virus (AAV)-based gene therapy candidate for people with adrenomyeloneuropathy (AMN). SBT101 was also shown to be well-tolerated in non-human primates through six months post-treatment.
Lead Product(s): SBT101
Therapeutic Area: Genetic Disease Product Name: SBT101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
SBT101 is the first clinical-stage adeno-associated virus (AAV)-based gene therapy candidate for people with adrenomyeloneuropathy. In preclinical studies, SBT101 demonstrated dose-dependent improvement of disease markers and functional improvement in AMN mouse models.
Lead Product(s): SBT101
Therapeutic Area: Genetic Disease Product Name: SBT101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
Under the terms of the agreement, SwanBio will license the FunSel screening platform from Purespring to explore new targets for early-stage pipeline programs. SwanBio will have an option to develop any targets identified and to own and commercialise any molecules developed.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: Purespring Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 18, 2022
Details:
SBT101 is first clinical-stage adeno-associated virus (AAV)-based gene therapy candidate for people with adrenomyeloneuropathy (AMN). SBT101 was designed to compensate for the disease-causing ABCD1 mutation.
Lead Product(s): SBT101
Therapeutic Area: Genetic Disease Product Name: SBT101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
SwanBio’s latest round of financing will support the ongoing evolution into a fully integrated research and development organization, with an initial focus on the clinical advancement of SBT101, including plans to dose patients in a Phase 1/2 trial.
Lead Product(s): SBT101
Therapeutic Area: Genetic Disease Product Name: SBT101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Syncona Limited
Deal Size: $56.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 18, 2022
Details:
In all mouse model and NHP studies, IT administration of SBT101 was well tolerated at doses predicted to be clinically relevant in people with AMN, and no drug-associated adverse events were noted.
Lead Product(s): SBT101
Therapeutic Area: Genetic Disease Product Name: SBT101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
